Hiroki Kobayashi1, Krystyna A Gieniec2, Tamsin R M Lannagan2, Tongtong Wang2, Naoya Asai3, Yasuyuki Mizutani4, Tadashi Iida4, Ryota Ando5, Elaine M Thomas2, Akihiro Sakai5, Nobumi Suzuki6, Mari Ichinose2, Josephine A Wright7, Laura Vrbanac2, Jia Q Ng2, Jarrad Goyne2, Georgette Radford2, Matthew J Lawrence8, Tarik Sammour9, Yoku Hayakawa10, Sonja Klebe11, Alice E Shin12, Samuel Asfaha13, Mark L Bettington14, Florian Rieder15, Nicholas Arpaia16, Tal Danino17, Lisa M Butler2, Alastair D Burt18, Simon J Leedham19, Anil K Rustgi20, Siddhartha Mukherjee21, Masahide Takahashi22, Timothy C Wang21, Atsushi Enomoto23, Susan L Woods24, Daniel L Worthley25. 1. Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia; South Australian Health and Medical Research Institute (SAHMRI), Adelaide, South Australia, Australia; Department of Pathology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan; Division of Molecular Pathology, Center for Neurological Disease and Cancer, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan. 2. Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia; South Australian Health and Medical Research Institute (SAHMRI), Adelaide, South Australia, Australia. 3. Department of Molecular Pathology, Graduate School of Medicine, Fujita Health University, Toyoake, Aichi, Japan. 4. Department of Pathology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan; Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan. 5. Department of Pathology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan. 6. Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia; South Australian Health and Medical Research Institute (SAHMRI), Adelaide, South Australia, Australia; Department of Gastroenterology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan. 7. South Australian Health and Medical Research Institute (SAHMRI), Adelaide, South Australia, Australia. 8. Colorectal Unit, Department of Surgery, Royal Adelaide Hospital, Adelaide, South Australia, Australia. 9. Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia; South Australian Health and Medical Research Institute (SAHMRI), Adelaide, South Australia, Australia; Colorectal Unit, Department of Surgery, Royal Adelaide Hospital, Adelaide, South Australia, Australia. 10. Department of Gastroenterology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan. 11. Department of Anatomical Pathology, Flinders Medical Centre, Bedford Park, Adelaide, South Australia, Australia. 12. Pathology and Laboratory Medicine, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada. 13. Department of Medicine, University of Western Ontario, London, Ontario, Canada. 14. Envoi Specialist Pathologists, Kelvin Grove, Queensland, Australia; Faculty of Medicine, University of Queensland, Herston, Queensland, Australia; QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia. 15. Department of Gastroenterology, Hepatology, and Nutrition, Digestive Diseases and Surgery Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA; Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA. 16. Department of Microbiology and Immunology, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York, USA; Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York, USA. 17. Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York, USA; Department of Biomedical Engineering, Columbia University, New York, New York, USA. 18. Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia; Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom. 19. Intestinal Stem Cell Biology Lab, Wellcome Trust Centre Human Genetics, University of Oxford, Oxford, United Kingdom. 20. Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York, USA. 21. Department of Medicine and Irving Cancer Research Center, Columbia University, New York, New York, USA. 22. Department of Pathology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan; Division of Molecular Pathology, Center for Neurological Disease and Cancer, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan; International Center for Cell and Gene Therapy, Fujita Health University, Toyoake, Aichi, Japan. 23. Department of Pathology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan. Electronic address: enomoto@iar.nagoya-u.ac.jp. 24. Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia; South Australian Health and Medical Research Institute (SAHMRI), Adelaide, South Australia, Australia. Electronic address: susan.woods@adelaide.edu.au. 25. South Australian Health and Medical Research Institute (SAHMRI), Adelaide, South Australia, Australia; GastroIntestinal Endoscopy, Lutwyche, Queensland, Australia. Electronic address: dan@colonoscopyclinic.com.au.
Abstract
BACKGROUND & AIMS: Cancer-associated fibroblasts (CAFs) play an important role in colorectal cancer (CRC) progression and predict poor prognosis in CRC patients. However, the cellular origins of CAFs remain unknown, making it challenging to therapeutically target these cells. Here, we aimed to identify the origins and contribution of colorectal CAFs associated with poor prognosis. METHODS: To elucidate CAF origins, we used a colitis-associated CRC mouse model in 5 different fate-mapping mouse lines with 5-bromodeoxyuridine dosing. RNA sequencing of fluorescence-activated cell sorting-purified CRC CAFs was performed to identify a potential therapeutic target in CAFs. To examine the prognostic significance of the stromal target, CRC patient RNA sequencing data and tissue microarray were used. CRC organoids were injected into the colons of knockout mice to assess the mechanism by which the stromal gene contributes to colorectal tumorigenesis. RESULTS: Our lineage-tracing studies revealed that in CRC, many ACTA2+ CAFs emerge through proliferation from intestinal pericryptal leptin receptor (Lepr)+ cells. These Lepr-lineage CAFs, in turn, express melanoma cell adhesion molecule (MCAM), a CRC stroma-specific marker that we identified with the use of RNA sequencing. High MCAM expression induced by transforming growth factor β was inversely associated with patient survival in human CRC. In mice, stromal Mcam knockout attenuated orthotopically injected colorectal tumoroid growth and improved survival through decreased tumor-associated macrophage recruitment. Mechanistically, fibroblast MCAM interacted with interleukin-1 receptor 1 to augment nuclear factor κB-IL34/CCL8 signaling that promotes macrophage chemotaxis. CONCLUSIONS: In colorectal carcinogenesis, pericryptal Lepr-lineage cells proliferate to generate MCAM+ CAFs that shape the tumor-promoting immune microenvironment. Preventing the expansion/differentiation of Lepr-lineage CAFs or inhibiting MCAM activity could be effective therapeutic approaches for CRC.
BACKGROUND & AIMS: Cancer-associated fibroblasts (CAFs) play an important role in colorectal cancer (CRC) progression and predict poor prognosis in CRC patients. However, the cellular origins of CAFs remain unknown, making it challenging to therapeutically target these cells. Here, we aimed to identify the origins and contribution of colorectal CAFs associated with poor prognosis. METHODS: To elucidate CAF origins, we used a colitis-associated CRC mouse model in 5 different fate-mapping mouse lines with 5-bromodeoxyuridine dosing. RNA sequencing of fluorescence-activated cell sorting-purified CRC CAFs was performed to identify a potential therapeutic target in CAFs. To examine the prognostic significance of the stromal target, CRC patient RNA sequencing data and tissue microarray were used. CRC organoids were injected into the colons of knockout mice to assess the mechanism by which the stromal gene contributes to colorectal tumorigenesis. RESULTS: Our lineage-tracing studies revealed that in CRC, many ACTA2+ CAFs emerge through proliferation from intestinal pericryptal leptin receptor (Lepr)+ cells. These Lepr-lineage CAFs, in turn, express melanoma cell adhesion molecule (MCAM), a CRC stroma-specific marker that we identified with the use of RNA sequencing. High MCAM expression induced by transforming growth factor β was inversely associated with patient survival in human CRC. In mice, stromal Mcam knockout attenuated orthotopically injected colorectal tumoroid growth and improved survival through decreased tumor-associated macrophage recruitment. Mechanistically, fibroblast MCAM interacted with interleukin-1 receptor 1 to augment nuclear factor κB-IL34/CCL8 signaling that promotes macrophage chemotaxis. CONCLUSIONS: In colorectal carcinogenesis, pericryptal Lepr-lineage cells proliferate to generate MCAM+ CAFs that shape the tumor-promoting immune microenvironment. Preventing the expansion/differentiation of Lepr-lineage CAFs or inhibiting MCAM activity could be effective therapeutic approaches for CRC.
Authors: Berna C Özdemir; Tsvetelina Pentcheva-Hoang; Julienne L Carstens; Xiaofeng Zheng; Chia-Chin Wu; Tyler R Simpson; Hanane Laklai; Hikaru Sugimoto; Christoph Kahlert; Sergey V Novitskiy; Ana De Jesus-Acosta; Padmanee Sharma; Pedram Heidari; Umar Mahmood; Lynda Chin; Harold L Moses; Valerie M Weaver; Anirban Maitra; James P Allison; Valerie S LeBleu; Raghu Kalluri Journal: Cancer Cell Date: 2014-05-22 Impact factor: 31.743
Authors: Daniel L Worthley; Michael Churchill; Jocelyn T Compton; Yagnesh Tailor; Meenakshi Rao; Yiling Si; Daniel Levin; Matthew G Schwartz; Aysu Uygur; Yoku Hayakawa; Stefanie Gross; Bernhard W Renz; Wanda Setlik; Ashley N Martinez; Xiaowei Chen; Saqib Nizami; Heon Goo Lee; H Paco Kang; Jon-Michael Caldwell; Samuel Asfaha; C Benedikt Westphalen; Trevor Graham; Guangchun Jin; Karan Nagar; Hongshan Wang; Mazen A Kheirbek; Alka Kolhe; Jared Carpenter; Mark Glaire; Abhinav Nair; Simon Renders; Nicholas Manieri; Sureshkumar Muthupalani; James G Fox; Maximilian Reichert; Andrew S Giraud; Robert F Schwabe; Jean-Phillipe Pradere; Katherine Walton; Ajay Prakash; Deborah Gumucio; Anil K Rustgi; Thaddeus S Stappenbeck; Richard A Friedman; Michael D Gershon; Peter Sims; Tracy Grikscheit; Francis Y Lee; Gerard Karsenty; Siddhartha Mukherjee; Timothy C Wang Journal: Cell Date: 2015-01-15 Impact factor: 41.582
Authors: Maximilian Reichert; Shigetsugu Takano; Johannes von Burstin; Sang-Bae Kim; Ju-Seog Lee; Kaori Ihida-Stansbury; Christopher Hahn; Steffen Heeg; Günter Schneider; Andrew D Rhim; Ben Z Stanger; Anil K Rustgi Journal: Genes Dev Date: 2013-01-25 Impact factor: 11.361
Authors: Ainhoa Arina; Christian Idel; Elizabeth M Hyjek; Maria-Luisa Alegre; Ying Wang; Vytautas P Bindokas; Ralph R Weichselbaum; Hans Schreiber Journal: Proc Natl Acad Sci U S A Date: 2016-06-17 Impact factor: 11.205
Authors: Paige N Vega; Avlant Nilsson; Manu P Kumar; Hiroaki Niitsu; Alan J Simmons; James Ro; Jiawei Wang; Zhengyi Chen; Brian A Joughin; Wei Li; Eliot T McKinley; Qi Liu; Joseph T Roland; M Kay Washington; Robert J Coffey; Douglas A Lauffenburger; Ken S Lau Journal: Front Oncol Date: 2022-05-04 Impact factor: 5.738